Skip to Content
MilliporeSigma
All Photos(2)

Documents

M4659

Sigma-Aldrich

Milrinone

≥97% (TLC), powder, phosphodiesterase type III inhibitor

Synonym(s):

1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C12H9N3O
CAS Number:
78415-72-2
Molecular Weight:
211.22
EC Number:
278-903-6
MDL number:
MFCD00133539
UNSPSC Code:
41106305
PubChem Substance ID:
24278060
NACRES:
NA.77

product name

Milrinone, ≥97% (TLC), powder

Quality Level

200

assay

≥97% (TLC)

form

powder

color

off-white

solubility

DMSO: >10 mg/mL
H2O: insoluble

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

CC1=C(C=C(C#N)C(=O)N1)c2ccncc2

InChI

1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)

InChI key

PZRHRDRVRGEVNW-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139) , PDE3B(5140) , PDE4B(5142) , PDE5A(8654) , PTPRA(5786)
rat ... Pde3a(50678)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Phosphodiesterase type III inhibitor; cAMP-specific, cGMP-inhibitable; potent cardiotonic, positive inotropic vasodilator.

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Krams et al.
American heart journal, 121(6 Pt 2), 1951-1955 (1991-06-01)
Bipyridine derivatives have recently been introduced as a new class of inodilator drugs in the intravenous therapy of heart failure. A member of this class is milrinone, which improves the inotropic state and reduces ventricular afterload, leading to improved hemodynamics.
Maria Otilia Bianchi et al.
Shock (Augusta, Ga.), 44(2), 115-120 (2015-04-22)
Despite the advancement in the postoperative care of neonates with congenital heart disease (CHD), there is little information on preoperative management of systemic and regional hemodynamics, which may be related to outcomes. We aimed to determine the preoperative effect of
Jerrold H Levy et al.
The Annals of thoracic surgery, 73(1), 325-330 (2002-02-09)
Phosphodiesterase inhibitors including milrinone produce positive inotropic effects by slowing the hydrolysis of cyclic adenosine monophosphate in the myocardium. With a loading dose of 50 microg/kg followed by an infusion of 0.5 microg x kg(-1) x min(-1), milrinone increases stroke
Marcelo Lannes et al.
Neurocritical care, 16(3), 354-362 (2012-04-25)
For the treatment of cerebral vasospasm, current therapies have focused on increasing blood flow through blood pressure augmentation, hypervolemia, the use of intra-arterial vasodilators, and angioplasty of proximal cerebral vessels. Through a large case series, we present our experience of
Dirk Bassler et al.
The Cochrane database of systematic reviews, (11)(11), CD007802-CD007802 (2010-11-12)
Persistent pulmonary hypertension of the newborn (PPHN) is a clinical syndrome characterized by suboptimal oxygenation as a result of sustained elevation in pulmonary vascular resistance after birth. Currently, the therapeutic mainstay for PPHN is optimal lung inflation and selective vasodilatation
View All Related Papers

Articles

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service